contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforias-product-portfolio-expands-with-new-ce-ivd-approved-solution-for-breast-cancer-diagnostics

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Analyst

Frans-Mikael Rostedt

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Question: Scanners have been a bottleneck for customers. Will Aiforia in any way support its customers in the scanner procurement process (e.g., centralized procurement from specific suppliers regionally → with benefits such as potential volume discounts and faster deliveries based on forecasts) to accelerate adoption?

Questions:  Sales efficiency, i.e., LTV growth, but how does this scalability efficiency factor develop? (Scalable SaaS company: customer value vs LTV growth and cost of acquiring growth) Partnerships, integration, and ecosystems with large equipment suppliers: how does partner sales develop (bottlenecks, ecosystem, Aiforia integration & switching cost) Cash flow development: Is the current cash sufficient for cash flow to turn positive?

Tomorrow, Aiforia will participate in Inderes’ company evening, which includes the company’s presentation and a Q&A session. Questions can be submitted via chat during the event or through the forum. Messages sent here by tomorrow morning will still be received.

When one really doesn’t want to trust only the company’s own announcements… Inderes, of course, also hypes it up, but but.. a feather in their cap, of course, if it breaks through. Or their reputation goes, if they still have any  Also here, just among other players                   Lumea – 18 Sep 24              Top 10 AI Companies for Digital Pathology | Lumea    Artificial Intelligence is advancing digital pathology and improving patient care. Here are the top AI companies that are leading the charge.         Est. reading time: 7 minutes

This case study published on Aiforia’s website at the end of November was interesting. In this study, a deep learning model created and trained with Aiforia Create successfully predicted the effectiveness of chemotherapy better than previously possible based on traditional clinical data. As I understand it, competitors haven’t really offered such deep learning AI.            aiforia.com              Case study: predicting the outcome of neoadjuvant chemotherapy for breast...    Dr. Sturm et al. used Aiforia® Create to develop an AI model to predict the outcome of neoadjuvant chemotherapy for breast cancer patients, pre-operation.

Should this be updated, as it was already the same in 01.2024. One could reach a profit with about 20 million in revenue, which is “only” 6 times the current one. In God’s hands

As I recall, the CEO expects 27 items to turn positive regarding operating profit.

Aiforia Technologies

This solution is Aiforia's ninth to receive CE-IVD approval in Europe. However, unlike previous approvals, the solution includes five separate AI models, so the approval significantly expands the company's product portfolio (8 models + 1 viewer -> 13 models + 1 viewer). The approval increases the potential scale of the company's new customer agreements and also enables larger expansions for existing customers.

Translation: Original published in Finnish on 6/24/2025 at 1:41 pm EEST.
Aiforia announced a new CE-IVD marking for its clinical AI solution for breast cancer classification. According to the company, the approved AI solution automates breast cancer classification by supporting pathologists with five separate AI models. The solution accurately identifies invasive carcinoma and ductal carcinoma in situ variant (DCIS). In addition, it identifies and objectively counts the number of mitoses, tubule formation, and nuclear atypia according to the Nottingham classification system. Prior to the now approved solution, Aiforia already had four models supporting breast cancer diagnostics (KI-67, ER and PR cells, HER-2 classification).
This solution is Aiforia&apos;s ninth to receive CE-IVD approval in Europe. However, unlike previous approvals, the solution includes five separate AI models, so the approval significantly expands the company&apos;s product portfolio (8 models + 1 viewer -&gt; 13 models + 1 viewer). The approval increases the potential scale of the company&apos;s new customer agreements and also enables larger expansions for existing customers. The release supports our view that the company&apos;s revenue growth will accelerate during the current year, as well as supporting the company&apos;s competitive position in a rapidly emerging market.&#xa0;

	2024	25e	26e
Revenue	2.9	4.7	7.6
growth-%	18.9 %	65.7 %	60.0 %
EBIT (adj.)	-12.2	-11.9	-12.0
EBIT-% (adj.)	-427.8 %	-252.9 %	-158.1 %
EPS (adj.)	-0.41	-0.37	-0.38
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Aiforia's product portfolio expands with new CE-IVD approved solution for breast cancer diagnostics

Key Estimate Figures23/04

Forum discussions